Emendo and Takeda sign deal for gene editing technology

24 April 2019
takeda_big

Genome editing specialist Emendo Biotherapeutics has agreed a licensing deal with Takeda Pharmaceutical (TYO: 4502).

Under the terms of the deal, the Japanese pharma giant has secured an option to use OMNI, Emendo’s nuclease program, to edit two genes as part of its research and development efforts.

OMNI is designed to enable very specific gene editing which minimizes off target cuts and allows for highly focused therapeutic intervention in complex genetic diseases.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology